In patients with hepatic failure, whether acute or chronic, associated with renal damage, the use of slow therapies is recommended, as these are better tolerated in patients with hemodynamic instability compared to IHD [11]. There is a limitation in the clearance of other types of molecules, as only water-soluble solutes are extracted and not those bound to albumin. The gene discussed is ALB; the disease is liver failure.